What is the 13F Pro Quality Score for HAE?

13F Pro ranks HAEMONETICS CORP (HAE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HAE's current score at https://13fpro.ai/research/HAE (free sign-up required for the full ranking).

Which hedge funds own the most HAE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HAE include BlackRock,, Neuberger Berman Group, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/HAE as soon as new 13F filings post.

Where does 13F Pro source HAE data?

All HAEMONETICS CORP fundamentals and ownership data come directly from SEC EDGAR. HAEMONETICS CORP files with the SEC under CIK 313143. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HAE in?

HAEMONETICS CORP (HAE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HAE research updated on 13F Pro?

HAE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HAEMONETICS CORP(HAE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 313143 HAE stock profile & AI dashboard →

13F Pro Quality Score

61.1/100

Rank #818 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

41.6/100

Profitability

74.8/100

Balance Sheet

76.8/100

Earnings Quality

53.9/100

Free Cash Flow

76.4/100

Institutional Flow

42.2/100

Revenue Scale

54.8/100

Dilution Risk

37.1/100

HAE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HAEMONETICS CORP (HAE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HAE at 61.1/100 on a 32-signal composite quality model, placing it at rank #818 of 2,879 stocks — the top half of the AI-ranked universe. HAE scores in the top quartile across balance sheet strength (76.8), free cash flow (76.4). Shareholder dilution risk is elevated at 37.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), HAEMONETICS CORP reports quarterly revenue of $346.4M, net income of $-20.1M, free cash flow of $53.3M. Top institutional holders of HAE by reported 13-F value include BlackRock,, Neuberger Berman Group, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. HAE trades on the NYSE exchange and files with the SEC under CIK 313143. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HAE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HAEMONETICS CORP directly from SEC EDGAR. HAEMONETICS CORP's 13F Pro composite quality score has ranged between 8 and 72 since 2024, currently 61.1 — a declining long-term trajectory across 43 quarterly and live scoring snapshots.

✦

Fun facts about HAEMONETICS CORP

Quirks, history, and lore behind HAE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · mid-cap · listed on NYSE · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of $1 billion, with operations spanning more than 80 countries — not a household name, but hospitals worldwide depend on it.
3
The History
Founded in the 1970s, it grew by solving a very specific problem: how do you efficiently collect, separate, and process human blood outside the body?
4
The Secret
Its core business is blood management technology — machines and disposables that separate whole blood into its components so nothing goes to waste.
5
The Lore
It is a dominant player in apheresis — the process of drawing blood, harvesting a specific component like platelets or plasma, and returning the rest to the donor. Blood banks love it.
6
The Giveaway
Its name literally means "blood mechanics" in Greek, and its ticker HAE is about as on-the-nose as corporate branding gets.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2026

$346.4M

Net Income

Q4 2026

$-20.1M

Free Cash Flow

Q4 2026

$53.3M

D/E Ratio

Q4 2026

1.56

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-2.0% YoY

$1.33BFY 2026

FY23 $1.17BFY24 $1.31BFY25 $1.36BFY26 $1.33B

Net Income

+57932.3% YoY

$97.3MFY 2026

FY23 $115.4MFY24 $117.6MFY25 $167.7KFY26 $97.3M

Operating Income

-29.3% YoY

$156.7MFY 2026

FY23 $156.0MFY24 $164.9MFY25 $221.8MFY26 $156.7M

EPS (Diluted)

-38.1% YoY

$2.05FY 2026

FY23 $2.24FY24 $2.29FY25 $3.31FY26 $2.05

Total Assets

-2.2% YoY

$2.40BFY 2026

FY23 $1.93BFY24 $2.20BFY25 $2.45BFY26 $2.40B

Total Debt

-18.6% YoY

$1.24BFY 2026

FY23 $765.9MFY24 $807.8MFY25 $1.53BFY26 $1.24B

Op. Cash Flow

+61.4% YoY

$293.2MFY 2026

FY23 $273.1MFY24 $181.8MFY25 $181.7MFY26 $293.2M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.33B -2.0%	$1.36B +4.0%	$1.31B +12.0%	$1.17B +17.7%	$993.2M +14.1%	$870.5M
Net Income	$97.3M +57932.3%	$167.7K -99.9%	$117.6M +1.9%	$115.4M +166.1%	$43.4M -45.4%	$79.5M
Operating Income	$156.7M -29.3%	$221.8M +34.5%	$164.9M +5.7%	$156.0M +93.2%	$80.8M -10.0%	$89.7M
EPS (Diluted)	$2.05 -38.1%	$3.31 +44.5%	$2.29 +2.2%	$2.24 +166.7%	$0.84 -45.8%	$1.55
Total Assets	$2.40B -2.2%	$2.45B +11.6%	$2.20B +13.5%	$1.93B +4.0%	$1.86B +2.2%	$1.82B
Total Debt	$1.24B -18.6%	$1.53B +89.2%	$807.8M +5.5%	$765.9M -1.0%	$773.6M +9.3%	$707.6M
Operating Cash Flow	$293.2M +61.4%	$181.7M -0.0%	$181.8M -33.4%	$273.1M +58.5%	$172.3M +58.3%	$108.8M

AI Insight: HAE Financial Trends

Q1 2026 swung to operating loss despite revenue recovery, while debt fell sharply but equity eroded further.

• Revenue rebounded to $346M in Q1 2026 from $339M in Q4 2025, but operating income collapsed to -$23M from $67M.

• Total debt declined $284M to $1,245M in Q1 2026 from $1,529M in Q4 2025, the lowest level since Q2 2024.

• Operating cash flow remained positive at $71M in Q1 2026, but net income swung to -$20M loss from $45M profit.

⚠ Operating margin turned negative in Q1 2026 (-6.6%) after four consecutive quarters of positive double-digit margins.

⚠ Equity has declined 12% from peak of $911M in Q4 2025 to $796M in Q1 2026, eroding shareholder value despite debt reduction.

AI Insight: HAE Ratio Trends

Q1 2026 turned sharply negative across all profitability metrics, erasing gains from prior-year strength and signaling a material operational deterioration.

• Operating margin collapsed to -6.7% in Q1 2026 from 19.9% in Q4 2025; net margin fell to -5.8% from 13.2%.

• ROIC turned negative at -4.5% in Q1 2026 versus 11.0% in Q4 2025, ending a streak of double-digit returns.

• Debt-to-equity edged down to 1.56 in Q1 2026 from 1.68 in Q4 2025, but leverage remains elevated versus 1.35 in mid-2024.

⚠ Quarterly loss in Q1 2026 suggests either material one-off charge or operational breakdown; requires urgent clarification on sustainability.

⚠ ROE crashed to -10.1% in Q1 2026 from 19.6% in Q4 2025—steepest single-quarter swing in the dataset.

Get alerted when HAE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HAEMONETICS CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HAE

BlackRock, Inc.
$316.7M5,619,979 sh
Neuberger Berman Group LLC
$200.6M3,560,918 sh
AQR CAPITAL MANAGEMENT LLC
$185.7M3,356,543 sh
LINDEN ADVISORS LP
$180.5M189,401,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$144.2M2,559,316 sh
VANGUARD CAPITAL MANAGEMENT LLC
$117.8M2,090,389 sh
STATE STREET CORP
$99.9M1,772,898 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$77.9M1,383,004 sh
River Road Asset Management, LLC
$74.8M1,327,989 sh
DIMENSIONAL FUND ADVISORS LP
$74.7M1,326,057 sh

Fund	Value	Shares
BlackRock, Inc.	$316.7M	5,619,979
Neuberger Berman Group LLC	$200.6M	3,560,918
AQR CAPITAL MANAGEMENT LLC	$185.7M	3,356,543
LINDEN ADVISORS LP	$180.5M	189,401,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$144.2M	2,559,316
VANGUARD CAPITAL MANAGEMENT LLC	$117.8M	2,090,389
STATE STREET CORP	$99.9M	1,772,898
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$77.9M	1,383,004
River Road Asset Management, LLC	$74.8M	1,327,989
DIMENSIONAL FUND ADVISORS LP	$74.7M	1,326,057

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HAE on your watchlist

Track score changes the day HAEMONETICS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HAE a good stock to buy?

13F Pro's AI-powered analysis of HAEMONETICS CORP (HAE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HAE are available on the HAE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HAE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HAE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HAEMONETICS CORP's investment landscape.